IGGA
EPZM

Iron Gate Global Advisors’s Epizyme, Inc EPZM Stock Holding History

Iron Gate Global Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,542
Closed -$21K – 272
2018
Q2 		$21K Buy
+1,542
New +$24K 0.02% 120

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Iron Gate Global Advisors's EPZM Position: Q3 2018 in Review

Iron Gate Global Advisors sold out of Epizyme, Inc (EPZM) in Q3 2018, closing a stake of 1,542 shares — an estimated $21K sold.

Iron Gate Global Advisors first reported a position in EPZM in Q2 2018 and held it in 1 quarter. The position peaked at $21K in Q2 2018. 104 funds tracked by Wall St. Rank hold EPZM as of Q3 2018.

  • Iron Gate Global Advisors reported no remaining Epizyme, Inc position as of Q3 2018 after selling out during the quarter.
  • Iron Gate Global Advisors sold 1,542 Epizyme, Inc shares in Q3 2018, an estimated $21K.
  • Iron Gate Global Advisors first reported a position in Epizyme, Inc in Q2 2018 and held it in 1 quarter.
  • Iron Gate Global Advisors's Epizyme, Inc position peaked at $21K in Q2 2018.
  • 104 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2018.

Based on Iron Gate Global Advisors's 13F filing for Q3 2018, filed 16 Nov 2018.